Skip to content
lifestyle.jardal-paintball.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Eton Pharmaceuticals
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
May 22, 2026
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
May 20, 2026
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
May 14, 2026
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
May 12, 2026
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
May 4, 2026
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
May 1, 2026
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
April 27, 2026
Eton Pharmaceuticals Announces CFO Succession Plan
April 16, 2026
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
March 19, 2026
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
March 3, 2026
1
2
Next Page
→